S'abonner

Unlocking the effective alliance of β-lapachone and hydroxytyrosol against triple-negative breast cancer cells - 27/04/24

Doi : 10.1016/j.biopha.2024.116439 
Jesús Calahorra a, b, c, , 1 , José L. Blaya-Cánovas a, b, c, 1, Olivia Castellini-Pérez c, Ernesto Aparicio-Puerta d, Candela Cives-Losada e, f, Jose J.G. Marin e, f, Markel Rementeria c, Francisca E. Cara b, Araceli López-Tejada b, c, g, Carmen Griñán-Lisón b, c, g, Francesco Aulicino h, Imre Berger h, i, Juan A. Marchal b, Violeta Delgado-Almenta c, Sergio Granados-Principal b, c, g,
a UGC de Oncología Médica, Hospital Universitario de Jaén, Jaén 23007, Spain 
b Instituto de Investigación Biosanitaria ibs.GRANADA, University Hospitals of Granada-University of Granada, Granada 18100, Spain 
c GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, Granada 18016, Spain 
d Clinical Bioinformatics, Center for Bioinformatics, Saarland University, Saarbrücken 66123, Germany 
e Experimental Hepatology and Drug Targeting (HEVEFARM), University of Salamanca, IBSAL, Salamanca 37007, Spain 
f Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid 28029, Spain 
g Department of Biochemistry and Molecular Biology 2, Faculty of Pharmacy, University of Granada, Campus de Cartuja s/n, Granada 18071, Spain 
h BrisSynBio Bristol Synthetic Biology Centre, Biomedical Sciences, School of Biochemistry, University of Bristol, 1 Tankard's Close, Bristol BS8 1TD, UK 
i Max Planck Bristol Centre for Minimal Biology, School of Chemistry, University of Bristol, Cantock's Close, Bristol BS8 1TS, UK 

Corresponding authors at: GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, Granada 18016, Spain.GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional GovernmentGranada18016Spain

Abstract

Triple-negative breast cancer (TNBC) is characterised by its aggressiveness and resistance to chemotherapy, demanding the development of effective strategies against its unique characteristics. Derived from lapacho tree bark, β-lapachone (β-LP) selectively targets cancer cells with elevated levels of the detoxifying enzyme NQO1. Hydroxytyrosol (HT) is a phenolic compound derived from olive trees with important anticancer properties that include the inhibition of cancer stem cells (CSCs) and metastatic features in TNBC, as well as relevant antioxidant activities by mechanisms such as the induction of NQO1. We aimed to study whether these compounds could have synergistic anticancer activity in TNBC cells and the possible role of NQO1. For this pourpose, we assessed the impact of β-LP (0.5 or 1.5 μM) and HT (50 and 100 μM) on five TNBC cell lines. We demonstrated that the combination of β-LP and HT exhibits anti-proliferative, pro-apoptotic, and cell cycle arrest effects in several TNBC cells, including docetaxel-resistant TNBC cells. Additionally, it effectively inhibits the self-renewal and clonogenicity of CSCs, modifying their aggressive phenotype. However, the notable impact of the β-LP-HT combination does not appear to be solely associated with the levels of the NQO1 protein and ROS. RNA-Seq analysis revealed that the combination's anticancer activity is linked to a strong induction of endoplasmic reticulum stress and apoptosis through the unfolded protein response. In conclusion, in this study, we demonstrated how the combination of β-LP and HT could offer an affordable, safe, and effective approach against TNBC.

Le texte complet de cet article est disponible en PDF.

Graphical Abstract




 : 

Anticancer ROS-independent synergies between β-LP and HT in TNBC cells. The β-LP-HT combination induces antiproliferative and proapoptotic effects, effectively targeting stemness, even in Doc-resistant cells. These effects appear to be mediated by modulation of the ER stress response.


Anticancer ROS-independent synergies between β-LP and HT in TNBC cells. The β-LP-HT combination induces antiproliferative and proapoptotic effects, effectively targeting stemness, even in Doc-resistant cells. These effects appear to be mediated by modulation of the ER stress response.

Le texte complet de cet article est disponible en PDF.

Highlights

Synergistic β-LP-HT interaction: potent anti-proliferative & pro-apoptotic effects in TNBC cells.
β-LP-HT alters CD44/CD24, reducing self-renewal & clonogenicity, targeting cancer stem cells.
Effective against Docetaxel-resistant TNBC cells, offering a chemo-resistance solution.
RNA-Seq reveals β-LP-HT induces ER stress & apoptosis via unfolded protein response, explaining anticancer action.

Le texte complet de cet article est disponible en PDF.

Abbreviations : β-LP, CSCs, Doc, EMT, ER, HT, IC50, MSFE, PI, ROS, TNBC, UPR

Keywords : Triple-negative breast cancer, β-lapachone, Hydroxytyrosol, NQO1, Unfolded protein response


Plan


© 2024  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 174

Article 116439- mai 2024 Retour au numéro
Article précédent Article précédent
  • Senolytic drugs dasatinib and quercetin combined with Carboplatin or Olaparib reduced the peritoneal and adipose tissue metastasis of ovarian cancer
  • Lian Wang, Bing Xiong, Wei Lu, Yujie Cheng, Jihui Zhu, Guihai Ai, Xiaojie Zhang, Xiuni Liu, Zhongping Cheng
| Article suivant Article suivant
  • Intranasal administration of Escherichia coli Nissle expressing the spike protein of SARS-CoV-2 induces long-term immunization and prevents spike protein-mediated lung injury in mice
  • Giovanni Sarnelli, Alessandro Del Re, Irene Palenca, Silvia Basili Franzin, Jie Lu, Luisa Seguella, Aurora Zilli, Marcella Pesce, Sara Rurgo, Giovanni Esposito, Walter Sanseverino, Giuseppe Esposito

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.